Genmab CEO on possible settlement in dispute with Janssen: "I have no comment"
Genmab CEO Jan van de Winkel is not keen on commenting on the possibility of a settlement in the dispute between Genmab and partner Janssen concerning the distribution of earnings from the cancer drug Darzalex, according to Danish newspaper Børsen.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
Danish pharmaceutical company Genmab intends to defend the stances of the firm in its current dispute with its former partner Janssen Pharmaceuticals on the distribution of the earnings from the cancer drug Darzalex, according to Danish newspaper Børsen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Analyst: Genmab share price may double
For subscribers
Genmab drug becomes more accessible in the US
For subscribers
